Andria Rakotomalala
A5085515145- Glioma Diagnosis and Treatment
- ATP Synthase and ATPases Research
- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- TGF-β signaling in diseases
- Renal and related cancers
- Brain Tumor Detection and Classification
- Circular RNAs in diseases
- Cancer Research and Treatments
- RNA modifications and cancer
- MicroRNA in disease regulation
- Cancer-related Molecular Pathways
- Spine and Intervertebral Disc Pathology
- Radiation Therapy and Dosimetry
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Cell Adhesion Molecules Research
- Medical Imaging and Analysis
- CRISPR and Genetic Engineering
- Mitochondrial Function and Pathology
Centre Oscar Lambret
2020-2024
Inserm
2020-2024
Université de Lille
2021-2024
Centre National de la Recherche Scientifique
2020-2023
Centre Hospitalier Universitaire de Lille
2021-2023
Centre Léon Bérard
2023
Institut d’Hématologie et d’Oncologie Pédiatrique
2023
Institut Jacques Monod
2023
Université Paris Cité
2023
Centre de Recherche en Cancérologie de Lyon
2023
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is only established treatment, with median patient survival 9 to 11 months. ONC201 a DRD2 antagonist and ClpP agonist that has shown preclinical emerging clinical efficacy in DMG. However, further work needed identify mechanisms response DIPGs treatment determine whether recurring genomic features influence response. Using systems-biological approach,...
High-grade gliomas represent the most lethal class of pediatric tumors, and their resistance to both radio- chemotherapy is associated with a poor prognosis. Recurrent mutations affecting histone genes drive tumorigenesis some high-grade gliomas, H3K27M are notably characteristic subtype called DMG (Diffuse Midline Gliomas). This dominant negative mutation impairs H3K27 trimethylation, leading profound epigenetic modifications expression. Even though this was described as driver event in...
Pediatric diffuse midline gliomas (pDMG) are an aggressive type of childhood cancer with a fatal outcome. Their major epigenetic determinism has become clear, notably the identification K27M mutations in histone H3. However, synergistic oncogenic mechanisms that induce and maintain tumor cell phenotype have yet to be deciphered. In 20 30% cases, these tumors altered BMP signaling pathway mutation on I receptor ALK2, encoded by ACVR1 . potential impact non-mutated for is less clear. By...
Pediatric diffuse midline gliomas (pDMG) are an aggressive type of childhood cancer with a fatal outcome. Their major epigenetic determinism has become clear, notably the identification K27M mutations in histone H3. However, synergistic oncogenic mechanisms that induce and maintain tumor cell phenotype have yet to be deciphered. In 20 30% cases, these tumors altered BMP signaling pathway mutation on I receptor ALK2, encoded by ACVR1 . potential impact non-mutated for is less clear. By...
Pediatric diffuse midline gliomas (pDMG) are an aggressive type of childhood cancer with a fatal outcome. Their major epigenetic determinism has become clear, notably the identification K27M mutations in histone H3. However, synergistic oncogenic mechanisms that induce and maintain tumor cell phenotype have yet to be deciphered. In 20 30% cases, these tumors altered BMP signaling pathway mutation on I receptor ALK2, encoded by ACVR1. potential impact non-mutated for ACVR1 is less clear. By...
<p>All Supplementary Figures and their captions.</p>
<p>All Supplementary Tables</p>
<p>All Supplementary Figures and their captions.</p>
<p>All Supplementary Tables</p>
<div>Abstract<p>Diffuse midline gliomas (DMG), including diffuse intrinsic pontine (DIPGs), are the most lethal of childhood cancers. Palliative radiotherapy is only established treatment, with median patient survival 9-11 months. ONC201 a DRD2 antagonist and ClpP agonist that has shown preclinical emerging clinical efficacy in DMG. However, further work needed to identify mechanisms response DIPGs treatment determine whether recurring genomic features influence response. Using...
Abstract Pediatric diffuse midline gliomas (pDMG) are an aggressive type of childhood cancer with a fatal outcome. Their major epigenetic determinism has become clear, notably the identification K27M mutations in histone H3. However, synergistic oncogenic mechanisms that induce and maintain tumor cell phenotype have yet to be deciphered. In 20 30% cases, these tumors altered BMP signaling pathway mutation on I receptor ALK2, encoded by ACVR1. potential impact non-mutated for ACVR1 is less...
<p>All Supplementary Tables</p>
<p>All Supplementary Tables</p>
<div>Abstract<p>Diffuse midline gliomas (DMG), including diffuse intrinsic pontine (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is only established treatment, with median patient survival 9 to 11 months. ONC201 a DRD2 antagonist and ClpP agonist that has shown preclinical emerging clinical efficacy in DMG. However, further work needed identify mechanisms response DIPGs treatment determine whether recurring genomic features influence response. Using...
<div>Abstract<p>Diffuse midline gliomas (DMG), including diffuse intrinsic pontine (DIPGs), are the most lethal of childhood cancers. Palliative radiotherapy is only established treatment, with median patient survival 9-11 months. ONC201 a DRD2 antagonist and ClpP agonist that has shown preclinical emerging clinical efficacy in DMG. However, further work needed to identify mechanisms response DIPGs treatment determine whether recurring genomic features influence response. Using...
<p>All Supplementary Figures and their captions.</p>
<p>All Supplementary Figures and their captions.</p>
<div>Abstract<p>Diffuse midline gliomas (DMG), including diffuse intrinsic pontine (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is only established treatment, with median patient survival 9 to 11 months. ONC201 a DRD2 antagonist and ClpP agonist that has shown preclinical emerging clinical efficacy in DMG. However, further work needed identify mechanisms response DIPGs treatment determine whether recurring genomic features influence response. Using...
<p>All Supplementary Tables</p>
<p>All Supplementary Figures and their captions.</p>
<p>All Supplementary Tables</p>